Conversely, TLR4 inhibition with TAK-242 enhances radiosensitivity both in vitro and in vivo, suggesting a promising therapeutic strategy that may become clinically viable in the near future and improve outcomes in NSCLC patients. Here, TLR4 is linked to non-small cell lung carcinoma.